Asia-Pacific Americas Africa Europe Middle East

NOVUGEN PHARMA SDN BHD 20140101

Company Profile:

BUSINESS TYPE

Manufacturer (Factory)

COMPANY NAME

Novugen Pharma Sdn. Bhd.

REGISTRATION NUMBER

201401016331 (1092417-D)

ESTABLISHMENT YEAR

2014

LOCATION

Bandar Enstek, Negeri Sembilan, Malaysia

COMPANY OVERVIEW

Novugen Pharma Sdn. Bhd. is a premier, vertically integrated pharmaceutical manufacturing company. It is classified as a Manufacturer (Factory) rather than a trader. The company operates a state-of-the-art research and development (R&D) center and an advanced manufacturing facility built in compliance with global regulatory standards, including the US FDA and PIC/S.

Novugen specializes in the development, formulation, commercial production, and global distribution of high-quality, affordable generic medicines, with a particular focus on oncology (cancer) therapeutics and other highly potent active substances.

KEY capabilities

1. Research and Development: In-house formulation and analytical development for complex generics.

2. Advanced Manufacturing: High-containment facilities for producing oral solid dosages and sterile injectables.

3. Quality Assurance: Strict adherence to international Good Manufacturing Practices (GMP).

CONCLUSION

Novugen Pharma is a high-tech pharmaceutical factory (manufacturer) with complete R&D and production capabilities, serving global healthcare markets directly from its facilities in Malaysia.

Enterprise Products

NOVUGEN PHARMA SDN BHD PRODUCT PORTFOLIO

Novugen Pharma is a pharmaceutical company based in Malaysia specializing in high-tech, niche, and hard-to-source generic medicines, with a primary focus on oncology (cancer) therapeutics.

Below is the list of products and categories manufactured and sold by Novugen Pharma:

PRODUCT CATEGORIES

1. ONCOLOGY ORAL SOLID DOSAGES

- Abiraterone Acetate (Used for prostate cancer treatment)

- Imatinib (Used for leukemia and gastrointestinal tumor treatment)

- Gefitinib (Used for non-small cell lung cancer treatment)

- Erlotinib (Used for lung and pancreatic cancer treatment)

- Temozolomide (Used for brain tumor treatment)

- Capecitabine (Used for breast and colorectal cancer treatment)

- Anastrozole (Used for breast cancer treatment)

- Letrozole (Used for breast cancer treatment)

- Exemestane (Used for breast cancer treatment)

2. ONCOLOGY INJECTABLES

- Bortezomib (Used for multiple myeloma treatment)

- Pemetrexed (Used for pleural mesothelioma and lung cancer treatment)

- Bendamustine (Used for leukemia and lymphoma treatment)

3. ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)

Novugen develops and manufactures high-potency APIs internally for oncology and other therapeutic areas to ensure vertical integration and supply security.

4. OTHER THERAPEUTIC AREAS

In addition to oncology, Novugen is expanding its portfolio into other complex therapeutic areas, including:

- Cardiovascular medicines

- Central Nervous System (CNS) therapeutics

- Antiviral drugs

MANUFACTURING AND R&D CAPABILITIES

All products are developed and manufactured at Novugen's state-of-the-art facilities located in Bandar Enstek, Negeri Sembilan, Malaysia. The facilities comply with international standards including PIC/S GMP, USFDA, and EU GMP.

Business Registration Information:

Manager:

Dr. P. K. Leong (CEO)

Phone:

No Data

E-mail:

info@novugenpharma.com

Official Website:
Address:

Lot 20, Jalan Teknologi 3/5A, Taman Sains Selangor Fasa 1, 47810 Kota Damansara, Petaling Jaya, Selangor, Malaysia

This content is from AI, the data and information provided is for reference only and is not applicable to investment and purchase decisions. If there is any incorrect information, please contact customer service to correct it.